Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses

Jeffrey W. Norris 1Department of Pharmacology, College of Graduate Studies, Midwestern University, Glendale, AZ 85308.

Search for other papers by Jeffrey W. Norris in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Johanna L. Watson 2Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Johanna L. Watson in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Fern Tablin 3Department of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Fern Tablin in
Current site
Google Scholar
PubMed
Close
 VMD, PhD
,
Tania A. Kozikowski 5Idexx Laboratories Inc, 1 Idexx Dr, Westbrook, ME 04092.

Search for other papers by Tania A. Kozikowski in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Heather K. Knych 4Department of Veterinary Molecular Biosciences and the K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Heather K. Knych in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

OBJECTIVE

To determine pharmacokinetics and pharmacodynamics after oral administration of a single dose of clopidogrel to horses.

ANIMALS

6 healthy adult horses.

PROCEDURES

Blood samples were collected before and at various times up to 24 hours after oral administration of clopidogrel (2 mg/kg). Reactivity of platelets from each blood sample was determined by optical aggregometry and phosphorylation of vasodilator-stimulated phosphoprotein (VASP). Concentrations of clopidogrel and the clopidogrel active metabolite derivative (CAMD) were measured in each blood sample by use of liquid chromatography–tandem mass spectrometry, and pharmacokinetic parameters were determined with a noncompartmental model.

RESULTS

Compared with results for preadministration samples, platelet aggregation in response to 12.5μM ADP decreased significantly within 4 hours after clopidogrel administration for 5 of 6 horses. After 24 hours, platelet aggregation was identical to that measured before administration. Platelet aggregation in response to 25μM ADP was identical between samples obtained before and after administration. Phosphorylation of VASP in response to ADP (20μM) and prostaglandin E1 (3.3μM) was also unchanged by administration of clopidogrel. Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.

CONCLUSIONS AND CLINICAL RELEVANCE

Clopidogrel or CAMD caused competitive inhibition of ADP-induced platelet aggregation during the first 24 hours after clopidogrel administration. Because CAMD was rapidly eliminated from horses, clopidogrel administration may be needed more frequently than in other species in which clopidogrel causes irreversible platelet inhibition. (Am J Vet Res 2019;80:505–512)

Abstract

OBJECTIVE

To determine pharmacokinetics and pharmacodynamics after oral administration of a single dose of clopidogrel to horses.

ANIMALS

6 healthy adult horses.

PROCEDURES

Blood samples were collected before and at various times up to 24 hours after oral administration of clopidogrel (2 mg/kg). Reactivity of platelets from each blood sample was determined by optical aggregometry and phosphorylation of vasodilator-stimulated phosphoprotein (VASP). Concentrations of clopidogrel and the clopidogrel active metabolite derivative (CAMD) were measured in each blood sample by use of liquid chromatography–tandem mass spectrometry, and pharmacokinetic parameters were determined with a noncompartmental model.

RESULTS

Compared with results for preadministration samples, platelet aggregation in response to 12.5μM ADP decreased significantly within 4 hours after clopidogrel administration for 5 of 6 horses. After 24 hours, platelet aggregation was identical to that measured before administration. Platelet aggregation in response to 25μM ADP was identical between samples obtained before and after administration. Phosphorylation of VASP in response to ADP (20μM) and prostaglandin E1 (3.3μM) was also unchanged by administration of clopidogrel. Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.

CONCLUSIONS AND CLINICAL RELEVANCE

Clopidogrel or CAMD caused competitive inhibition of ADP-induced platelet aggregation during the first 24 hours after clopidogrel administration. Because CAMD was rapidly eliminated from horses, clopidogrel administration may be needed more frequently than in other species in which clopidogrel causes irreversible platelet inhibition. (Am J Vet Res 2019;80:505–512)

All Time Past Year Past 30 Days
Abstract Views 158 0 0
Full Text Views 896 630 37
PDF Downloads 437 196 22
Advertisement